I-Mab Biopharma (IMAB) Misses Q2 EPS by 3c

I-Mab Biopharma (NASDAQ: IMAB) reported Q2 EPS of ($0.07), $0.03 worse than the analyst estimate of ($0.04).

For earnings history and earnings-related data on I-Mab Biopharma (IMAB) click here.

You May Also Be Interested In

• EyePoint Pharmaceuticals (EYPT) call put ratio 1.4 calls to 1 put as share price up 8.9%
• Canadian and U.S. negotiators plan last-minute talks ahead of midnight tariff deadline - CBC News
• Kingsoft Cloud Holdings Limited (KC) 2200 contracts of August 10 puts trade